ADHD Treatment Portfolio Sold for $50 Million: Clearing Debt and Focusing on Rare Diseases

Zevra Therapeutics, Inc. (Nasdaq: ZVRA) has entered into an agreement, effective March 16 local time, to sell its central nervous system drug portfolio—SDX, including AZSTARYS and KP-1077—to Commave Therapeutics SA for $50 million (approximately KRW 70 billion). Simultaneously, the company will terminate all pending litigation between the parties before the Delaware Court of Chancery. Prior to closing, Zevra fully repaid the remaining $63 million (about KRW 85 billion) balance on its term loan, becoming debt-free, and announced plans to concentrate its management resources on its rare disease pipeline and commercialization efforts.

In its full-year 2025 and fourth-quarter results released on March 9, Zevra reported profitability for 2025, driven by sales growth of its Niemann–Pick disease type C therapy, MIPLYFFA. In 2024, the company expanded its rare-disease revenue base by selling priority review vouchers for pediatric rare diseases for roughly $150 million and securing U.S. Food and Drug Administration (FDA) approval for MIPLYFFA.

Zevra, a Nasdaq-listed biotech specializing in rare diseases, employs a data-driven development strategy to create and market treatments for conditions with limited options, such as Niemann–Pick disease type C and vascular Ehlers-Danlos syndrome. The divestiture of the SDX portfolio underscores Zevra’s strategic shift away from ADHD and sleep-disorder assets, refocusing capital and capabilities on its rare-disease therapy pipeline and commercial organization.